Tarsons Products

  • Market Cap: Small Cap
  • Industry: Healthcare Services
  • ISIN: INE144Z01023
  • NSEID: TARSONS
  • BSEID: 543399
INR
223.65
-4.95 (-2.17%)
BSENSE

Dec 05

BSE+NSE Vol: 40.54 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

40.54 k (-82.36%) Volume

Shareholding (Sep 2025)

FII

5.82%

Held by 13 FIIs

DII

0.08%

Held by 0 DIIs

Promoter

47.31%

Who are the top shareholders of the Tarsons Products?

06-Jun-2025

The top shareholders of Tarsons Products include Sanjive Sehgal with 26.98%, Clear Vision Investment Holdings Pte Limited at 23.42%, and 16 Foreign Institutional Investors holding a combined 9.52%. Individual investors own 15.3% of the shares.

The top shareholders of Tarsons Products include the promoters, with Sanjive Sehgal holding the highest stake at 26.98%. Additionally, Clear Vision Investment Holdings Pte Limited is the largest public shareholder, owning 23.42%. The company also has 16 Foreign Institutional Investors (FIIs) holding a combined 9.52% of the shares. Individual investors collectively hold 15.3% of the company's shares.

Read More

What does Tarsons Products do?

06-Jun-2025

Tarsons Products Ltd is a small-cap company in the healthcare services industry, incorporated in 1983 and converted to a public company in 2021. As of March 2025, it reported net sales of ₹113 Cr and a net profit of ₹10 Cr, with a market cap of ₹2,028 Cr.

Overview:<BR>Tarsons Products Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History:<BR>Tarsons Products Limited was incorporated as Tarsons Products Private Limited in 1983 and was converted into a Public Limited Company on June 14, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 113 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 10 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 2,028 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 68.00<BR>- Industry P/E: 41<BR>- Dividend Yield: 0.52%<BR>- Debt Equity: 0.50<BR>- Return on Equity: 4.72%<BR>- Price to Book: 3.23<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Who are in the management team of Tarsons Products?

06-Jun-2025

As of March 2023, the management team of Tarsons Products includes Sanjive Sehgal (Chairman & Managing Director), Rohan Sehgal (Whole-time Director), and several independent directors, along with Santosh Kumar Agrawal (CFO & Company Secretary). They oversee the company's governance and operations.

As of March 2023, the management team of Tarsons Products includes:<BR><BR>1. Sanjive Sehgal - Chairman & Managing Director<BR>2. Rohan Sehgal - Whole-time Director<BR>3. Gaurav Podar - Nominee<BR>4. Viresh Oberai - Independent Director<BR>5. Sucharita Basu - Independent Director<BR>6. Girish Paman Vanvari - Independent Director<BR>7. Santosh Kumar Agrawal - Chief Finance Officer & Company Secretary<BR><BR>These individuals play key roles in the governance and operational management of the company.

Read More

Has Tarsons Products declared dividend?

06-Jun-2025

Yes, Tarsons Products Ltd has declared a 100% dividend, amounting to ₹2 per share, with an ex-date of September 20, 2024. However, the company has experienced negative total returns over various periods, indicating a decline in price performance despite the dividend declaration.

Tarsons Products Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.52%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.41%, the dividend return was 0%, resulting in a total return of -15.41%.<BR><BR>Over the past year, the price return was -8.35%, the dividend return was 0.47%, leading to a total return of -7.88%.<BR><BR>In the last 2 years, the price return was -33.53%, the dividend return was 0.35%, resulting in a total return of -33.18%.<BR><BR>For the 3-year period, the price return was -45.15%, the dividend return was 0.29%, culminating in a total return of -44.86%.<BR><BR>In the 4-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, both the price return and dividend return were 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Tarsons Products has declared a dividend, the total returns over various periods indicate a negative trend in price performance, with minimal contributions from dividends.

Read More

Who are the peers of the Tarsons Products?

16-Jul-2025

Tarsons Products' peers include Metropolis Health, Suven Life Sciences, Thyrocare Technologies, and others, with varying management risks and growth rates. Tarsons has below-average growth and the lowest 1-year return at -23.12% among its peers.

Peers: The peers of Tarsons Products are Metropolis Healt, Suven Life Scie., Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, Vimta Labs, Suraksha Diagno., 3B Blackbio, and Sastasundar Ven.<BR><BR>Quality Snapshot: Excellent management risk is observed at Laxmi Dental, while Good management risk is found at Metropolis Healt and Thyrocare Tech. Average management risk is present at Krsnaa Diagnost., Suraksha Diagno., and 3B Blackbio, and the rest have Below Average management risk, including Tarsons Products, Suven Life Scie., and Sastasundar Ven. Growth is Good at Laxmi Dental and Vimta Labs, while Below Average growth is noted for Metropolis Healt, Suven Life Scie., Thyrocare Tech, Krsnaa Diagnost, and Tarsons Products, with Average growth at Sastasundar Ven. Capital Structure is Excellent at Metropolis Healt, Thyrocare Tech, Krsnaa Diagnost, and Sastasundar Ven, Good at Laxmi Dental and Suraksha Diagno., and the rest have Average or Below Average ratings.<BR><BR>Return Snapshot: Suven Life Scie. has the highest 1-year return at 118.45%, while Tarsons Products has the lowest at -23.12%, indicating a significant underperformance compared to its peers. Additionally, Krsnaa Diagnost, Suraksha Diagno., 3B Blackbio, and Prevest Denpro have negative six-month returns.

Read More

How big is Tarsons Products?

24-Jul-2025

As of 24th July, Tarsons Products Ltd has a market capitalization of 2,127.00 Cr, with recent net sales of 392.42 Cr and a net profit of 29.77 Cr. The company's shareholder's funds are 612.86 Cr, and total assets amount to 972.18 Cr.

As of 24th July, Tarsons Products Ltd has a market capitalization of 2,127.00 Cr and is classified as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 392.42 Cr and a Net Profit of 29.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 612.86 Cr and Total Assets of 972.18 Cr.

Read More

When is the next results date for Tarsons Products?

07-Aug-2025

The next results date for Tarsons Products is 12 August 2025.

The next results date for Tarsons Products is scheduled for 12 August 2025.

Read More

Are Tarsons Products latest results good or bad?

12-Aug-2025

Tarsons Products' latest results are disappointing, with a Profit Before Tax of Rs -0.31 crore and a Profit After Tax of Rs 1.78 crore, both showing significant declines. The company's net sales and earnings per share have also dropped, leading to a 'Strong Sell' rating from MarketsMOJO, indicating a negative outlook.

The latest results for Tarsons Products are quite disappointing. The company has reported a significant decline in profitability, with a Profit Before Tax (PBT) of Rs -0.31 crore, which is a drastic drop of 104.3% compared to the average PBT of Rs 7.21 crore over the previous four quarters. Similarly, the Profit After Tax (PAT) has fallen to Rs 1.78 crore, marking a 76.1% decrease from the average PAT of Rs 7.44 crore.<BR><BR>Net sales have also decreased, standing at Rs 91.36 crore, which is a 6.9% decline from the average of Rs 98.11 crore. The earnings per share (EPS) have reached their lowest point in five quarters at Rs 0.33, indicating a troubling trend in profitability. Additionally, the company's cash and cash equivalents have decreased to Rs 8.45 crore, reflecting a deterioration in short-term liquidity.<BR><BR>Overall, these results suggest a concerning downturn for Tarsons Products, and the stock has been rated as a 'Strong Sell' by MarketsMOJO, further emphasizing the negative outlook.

Read More

Is Tarsons Products technically bullish or bearish?

19-Aug-2025

As of 18 August 2025, Tarsons Products has shifted to a bearish trend with moderate strength, indicated by bearish MACD and Bollinger Bands across multiple time frames, along with significant underperformance against the Sensex.

As of 18 August 2025, the technical trend for Tarsons Products has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish daily moving average. The KST is mildly bearish on the weekly and bearish on the monthly, while the Dow Theory shows no trend on the weekly and mildly bearish on the monthly. The stock has underperformed significantly against the Sensex over various periods, further supporting the bearish outlook.

Read More

How has been the historical performance of Tarsons Products?

13-Nov-2025

Tarsons Products has shown strong sales growth from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, but profitability metrics, including profit before tax and profit after tax, have declined during the same period. Total assets increased significantly, while total debt rose sharply, indicating higher leverage.

Answer:<BR>The historical performance of Tarsons Products shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Tarsons Products has experienced notable changes in its financial performance from March 2021 to March 2025. Net sales increased from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, indicating a strong growth trajectory. However, the total operating income followed a similar trend, rising from 228.91 Cr to 392.41 Cr during the same period. The total expenditure also rose significantly, from 125.48 Cr in March 2021 to 281.69 Cr in March 2025. Operating profit (PBDIT) peaked at 161.16 Cr in March 2022 but decreased to 126.68 Cr by March 2025. Profit before tax saw a decline from 92.43 Cr in March 2021 to 44.80 Cr in March 2025, while profit after tax also dropped from 68.87 Cr to 29.77 Cr in the same timeframe. The company's total assets increased from 295.95 Cr in March 2021 to 1,080.04 Cr in March 2025, reflecting substantial growth in its asset base. Conversely, total debt rose from 3.27 Cr to 328.56 Cr, indicating a significant increase in leverage. Overall, while Tarsons Products has shown growth in sales and assets, profitability metrics have declined in recent years.

Read More

Should I buy, sell or hold Tarsons Products?

14-Nov-2025

Is Tarsons Products overvalued or undervalued?

02-Dec-2025

As of December 1, 2025, Tarsons Products is considered overvalued with a PE ratio of 59.27, significantly higher than its peers, and has underperformed the market with a year-to-date return of -43.36%.

As of 1 December 2025, the valuation grade for Tarsons Products has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 59.27, an EV to EBIT of 40.66, and an EV to EBITDA of 13.33. These ratios suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.<BR><BR>In comparison to its peers, Tarsons Products' PE ratio is significantly higher than that of Finolex Industries, which stands at 22.79, indicating a stark contrast in valuation. Additionally, while Tarsons Products has a PEG ratio of 0.00, this is not favorable when compared to peers like Shaily Engineers, which has a PEG of 0.83, suggesting that Tarsons may not be justifying its high valuation through growth. The company's recent stock performance has been poor, with a year-to-date return of -43.36%, contrasting sharply with the Sensex's 9.60% return, further reinforcing the notion of overvaluation.

Read More

Why is Tarsons Products falling/rising?

05-Dec-2025

As of 04-Dec, Tarsons Products Ltd's stock price is declining at 228.60, down -1.21%, following a trend reversal and significant opening gap down. The stock has underperformed its sector and benchmark, with a year-to-date decline of -43.47% and a -68.74% drop over three years, indicating waning investor confidence and participation.

As of 04-Dec, Tarsons Products Ltd is experiencing a decline in its stock price, currently at 228.60, which reflects a change of -2.8 (-1.21%). This drop follows a trend reversal after three consecutive days of gains and is compounded by a significant opening gap down of -4.04% today. The stock has underperformed its sector by -1.87% and has shown a day’s low of Rs 222.05, indicating a lack of investor confidence.<BR><BR>The stock's performance over various periods reveals a concerning trend, with a year-to-date decline of -43.47% and a staggering -68.74% drop over the past three years, significantly underperforming the benchmark Sensex, which has gained 9.12% in the same timeframe. Additionally, the stock's operating profit has decreased at an annual rate of -18.84% over the last five years, and its latest profit after tax has fallen by -64.36% in the past six months.<BR><BR>Investor participation is also waning, as evidenced by a -78.26% drop in delivery volume compared to the five-day average, suggesting reduced interest from both retail and institutional investors. Institutional investors have decreased their stake by -3.27% in the previous quarter, which further indicates a lack of confidence in the stock's future performance.<BR><BR>Overall, the combination of poor financial results, declining investor participation, and consistent underperformance against benchmarks contributes to the stock's falling price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -18.84% of over the last 5 years

 
2

Negative results in Sep 25

3

With ROCE of 3.9, it has a Expensive valuation with a 1.6 Enterprise value to Capital Employed

4

Falling Participation by Institutional Investors

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 1,190 Cr (Small Cap)

stock-summary
P/E

59.00

stock-summary
Industry P/E

38

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.58

stock-summary
Return on Equity

3.28%

stock-summary
Price to Book

1.94

Revenue and Profits:
Net Sales:
102 Cr
(Quarterly Results - Sep 2025)
Net Profit:
3 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.11%
0%
-30.11%
6 Months
-41.6%
0%
-41.6%
1 Year
-49.69%
0%
-49.69%
2 Years
-52.13%
0.39%
-51.74%
3 Years
-69.48%
0.29%
-69.19%
4 Years
-66.25%
0.32%
-65.93%
5 Years
0%
0%
0.0%

Latest dividend: 2 per share ex-dividend date: Sep-20-2024

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

Is Tarsons Products overvalued or undervalued?

Understanding Tarsons Products’ Valuation Metrics

As of 1 December 2025, Tarsons Products exhibits a price-to-earnings (PE) ratio of 59.3, signalling a premium valuation relative to earnings. This is considerably higher than many of its peers, although some competitors in the healthcare services space command even loftier multiples. The price-to-book (P/B) ratio stands at 1.94, suggesting the stock trades nearly twice its book value, which is moderate but still indicative of investor confidence in the company’s asset utilisation.

Enterprise value (EV) multiples further illustrate the valuation landscape. The EV to EBIT ratio is notably elevated at 40.7, while EV to EBITDA is 13.3, reflecting expectations of strong operational cash flow generation despite modest profita...

Read More
Announcements stock-summary

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

28-Nov-2025 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mitsubishi UFJ Financial Group (MUFG) & First Sentier Investors (Hong Kong) Ltd

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Further Investment In Tarsons Life Science Pte. Ltd. A Wholly-Owned Subsidiary Of The Company.

27-Nov-2025 | Source : BSE

Further investment in Tarsons Life Science Pte. Ltd. a wholly Owned Subsidiary of the Company in Singapore to repay loans and other operational & financial obligations.

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

19-Nov-2025 | Source : BSE

Transcript of Earning Conference Call for the quarter ended September 30 2025

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Tarsons Products Ltd has declared 100% dividend, ex-date: 20 Sep 24

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
32.40%
EBIT Growth (5y)
-18.84%
EBIT to Interest (avg)
12.03
Debt to EBITDA (avg)
3.13
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.36
Tax Ratio
36.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.91%
ROCE (avg)
5.88%
ROE (avg)
9.82%
Valuation key factors
Factor
Value
P/E Ratio
59
Industry P/E
38
Price to Book Value
1.94
EV to EBIT
40.60
EV to EBITDA
13.31
EV to Capital Employed
1.59
EV to Sales
3.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.93%
ROE (Latest)
3.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 2 Schemes (0.0%)

FIIs

Held by 13 FIIs (5.82%)

Promoter with highest holding

Sanjive Sehgal (26.98%)

Highest Public shareholder

Clear Vision Investment Holdings Pte Limited (23.42%)

Individual Investors Holdings

17.14%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 12.95% vs -23.39% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 82.91% vs -77.30% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "80.51",
          "val2": "71.28",
          "chgp": "12.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "26.15",
          "val2": "22.23",
          "chgp": "17.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.41",
          "val2": "4.28",
          "chgp": "3.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "6.53",
          "val2": "3.57",
          "chgp": "82.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "32.48%",
          "val2": "31.19%",
          "chgp": "1.29%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 4.70% vs 12.48% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -47.91% vs -13.44% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "151.79",
          "val2": "144.97",
          "chgp": "4.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "48.38",
          "val2": "40.52",
          "chgp": "19.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.69",
          "val2": "8.88",
          "chgp": "-2.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "10.10",
          "val2": "19.39",
          "chgp": "-47.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "31.87%",
          "val2": "27.95%",
          "chgp": "3.92%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 15.98% vs -5.23% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -16.85% vs -43.91% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "221.13",
          "val2": "190.67",
          "chgp": "15.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "68.43",
          "val2": "69.56",
          "chgp": "-1.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "13.01",
          "val2": "5.87",
          "chgp": "121.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "27.00",
          "val2": "32.47",
          "chgp": "-16.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "30.95%",
          "val2": "36.48%",
          "chgp": "-5.53%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 32.40% vs -1.46% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -30.18% vs -57.64% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "392.41",
          "val2": "296.39",
          "chgp": "32.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "110.72",
          "val2": "99.81",
          "chgp": "10.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "19.39",
          "val2": "10.12",
          "chgp": "91.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "29.77",
          "val2": "42.64",
          "chgp": "-30.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "28.22%",
          "val2": "33.68%",
          "chgp": "-5.46%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
80.51
71.28
12.95%
Operating Profit (PBDIT) excl Other Income
26.15
22.23
17.63%
Interest
4.41
4.28
3.04%
Exceptional Items
0.00
0.00
Standalone Net Profit
6.53
3.57
82.91%
Operating Profit Margin (Excl OI)
32.48%
31.19%
1.29%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 12.95% vs -23.39% in Jun 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is 82.91% vs -77.30% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
151.79
144.97
4.70%
Operating Profit (PBDIT) excl Other Income
48.38
40.52
19.40%
Interest
8.69
8.88
-2.14%
Exceptional Items
0.00
0.00
Standalone Net Profit
10.10
19.39
-47.91%
Operating Profit Margin (Excl OI)
31.87%
27.95%
3.92%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 4.70% vs 12.48% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -47.91% vs -13.44% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
221.13
190.67
15.98%
Operating Profit (PBDIT) excl Other Income
68.43
69.56
-1.62%
Interest
13.01
5.87
121.64%
Exceptional Items
0.00
0.00
Standalone Net Profit
27.00
32.47
-16.85%
Operating Profit Margin (Excl OI)
30.95%
36.48%
-5.53%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 15.98% vs -5.23% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -16.85% vs -43.91% in Dec 2023

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
392.41
296.39
32.40%
Operating Profit (PBDIT) excl Other Income
110.72
99.81
10.93%
Interest
19.39
10.12
91.60%
Exceptional Items
0.00
0.00
Consolidate Net Profit
29.77
42.64
-30.18%
Operating Profit Margin (Excl OI)
28.22%
33.68%
-5.46%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 32.40% vs -1.46% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -30.18% vs -57.64% in Mar 2024

stock-summaryCompany CV
About Tarsons Products Ltd stock-summary
stock-summary
Tarsons Products Ltd
Small Cap
Healthcare Services
Tarsons Products Limited was incorporated as Tarsons Products Private Limited on July 5, 1983. The Company was subsequently converted into a Public Limited Company and the name of the Company was changed to Tarsons Products Limited on June 14, 2021.
Company Coordinates stock-summary
Icon
No Company Details Available